DiaMedica Therapeutics Inc.

Direct answer

DiaMedica Therapeutics Inc. is publicly traded on NASDAQ under the ticker DMAC.

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes....

Can you invest in DiaMedica Therapeutics Inc.?

Yes. DiaMedica Therapeutics Inc. trades publicly on NASDAQ as DMAC.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for DiaMedica Therapeutics Inc.

Detailed equity research is provided by MarketSnap.